Journal of Antimicrobial Chemotherapy (1996) 37, 161-167
© 1996 The British Society for Antimicrobial Chemotherapy
brief-report |
Penetration of cefuroxime into the cerebrospinal fluid of patients with traumatic brain injury
aDepartment of Surgery, Division of Trauma Surgery, Division of Infectious Diseased, University of Zürich, Medical School CH-8091 Zürich, Switzerland bDepartment of NeurosurgeryDivision of Infectious Diseased, University of Zürich, Medical School CH-8091 Zürich, Switzerland cDepartment of Internal Medicine, Division of Infectious Diseased, University of Zürich, Medical School CH-8091 Zürich, Switzerland
Received 24 March 1995; returned 21 June 1995; accepted 22 August 1995
*Corresponding author: Telephone +41–(1)–2551111; Fax: +41–(1)–2554406
Cefuroxime levels were measured in cerebrospinal fluid (CSF) and serum of four patients with traumatic brain injury following the implantation of intraventricular catheters. The levels ranged from 0.15 to 2.03 µg/mL in CSF and from 1.8 to 66.9 µg/mL in serum. No ventriculostomy related infections were detected.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  G. A Faich, J. Morganroth, A. B Whitehouse, J. S Brar, P. Arcuri, S. F Kowalsky, D. C Haverstock, R. A Celesk, and D. A Church Clinical Experience with Moxifloxacin in Patients with Respiratory Tract Infections Ann. Pharmacother., May 1, 2004; 38(5): 749 - 754. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. McFarland, F. Barkhof, J. Antel, and D. Miller The role of MRI as a surrogate outcome measure in multiple sclerosis Multiple Sclerosis, September 1, 2002; 8(1_suppl): 40 - 51. [Abstract] [PDF]
|
|
|
|
|
|
H F McFarland, F Barkhof, J Antel, and D H Miller The role of MRI as a surrogate outcome measure in multiple sclerosis Multiple Sclerosis, February 1, 2002; 8(1): 40 - 51. [Abstract] [PDF]
|
|
|
|
 |
|
 B. Darpo Spectrum of drugs prolonging QT interval and the incidence of torsades de pointes Eur. Heart J. Suppl., September 1, 2001; 3(suppl_K): K70 - K80. [Abstract] [PDF]
|
|
|
|
|
|
J. Morganroth Focus on issues in measuring and interpreting changes in the QTc interval duration Eur. Heart J. Suppl., September 1, 2001; 3(suppl_K): K105 - K111. [Abstract] [PDF]
|
|
|
|
|
|
L. Carlsson Drug-induced torsade de pointes: the perspectives of industry Eur. Heart J. Suppl., September 1, 2001; 3(suppl_K): K114 - K120. [Abstract] [PDF]
|
|
|
|
 |
|
 P. Petitpretz, P. Arvis, M. Marel, J. Moita, and J. Urueta Oral Moxifloxacin vs High-Dosage Amoxicillin in the Treatment of Mild-to-Moderate, Community-Acquired, Suspected Pneumococcal Pneumonia in Adults Chest, January 1, 2001; 119(1): 185 - 195. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Ball Quinolone generations: natural history or natural selection? J. Antimicrob. Chemother., July 1, 2000; 46(90003): 17 - 24. [Abstract] [Full Text]
|
|
|
|
|
|
P. Ball Quinolone-induced QT interval prolongation: a not-so-unexpected class effect J. Antimicrob. Chemother., May 1, 2000; 45(5): 557 - 559. [Full Text] [PDF]
|
|
|
|
 |
|
 A S. Davis The pre-clinical assessment of QT interval prolongation: a comparison of in vitro and in vivo methods Human and Experimental Toxicology, December 1, 1998; 17(12): 677 - 680. [Abstract] [PDF]
|
|